Navigation Links
Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Date:5/17/2011

WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).  In the study presented at the annual meeting of the American Urological Association, RAPAFLO(R) also significantly improved urinary symptoms as well as quality of life.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition characterized by persistent discomfort in the lower pelvic area and can have significant impact on quality of life. Symptoms can be severe and include painful and frequent urination and difficult or painful ejaculation. By definition, this type of prostatitis is not associated with a bacterial infection, and the cause is unknown. As many as 10 percent of men in North America have had or will have experienced prostatitis symptoms, and 90 percent of them have CP/CPPS. Evaluated in this trial for CP/CPPS, RAPAFLO(R) is a uniquely selective alpha blocker approved for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), commonly referred to as an enlarged prostate.

"In this well-controlled, double-blind study, RAPAFLO(R) has demonstrated significantly improved outcomes in men suffering from CP/CPPS," said J. Curtis Nickel, M.D., urologist at Kingston General Hospital and Professor of Urology at Queen's University in Kingston, Ontario, Canada, and lead author of the study. "Importantly, twice as many men treated with RAPAFLO 4 mg once daily versus placebo reported feeling a moderate to marked improvement in their condition, showing that the statistically significant findings also were clinically meaningful for the patients."

Study Results

In this Phase 2 study with 151 patients, compared with placebo, RAPAFLO(R) at a 4 mg dose significantly decreased the total score on the well-recognized National Institutes of Health Chronic Prostatitis Symptom Ind
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. Vanda Pharmaceuticals Reports First Quarter 2011 Results
7. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
8. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... Research and Markets has announced the addition ... In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to ... The global companion diagnostics market is expected to grow ... Factors such as rising need for personalized medicine in ... pharmaceutical industry, support from regulatory authorities, and emerging technologies ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced today that it ... exchange for 6,634 shares of CTI,s Series A, B ... interest of all,series of CTI,s Convertible Preferred Stock. Each ... 7,143 shares of CTI,s common stock, at a,conversion price ...
... $65.0 MillionRICHMOND, Calif., Feb. 4 Sangamo BioSciences, Inc. (Nasdaq: ... year 2008 financial results and accomplishments and provided an outlook ... Sangamo reported a consolidated net loss of $2.6 million, or ... million, or $0.17 per share, for the same period in ...
... Specialty Pharmacy is,pleased to announce two new "Navigator" ... DSP launched both a Hemophilia and IVIG,Navigator Program. ... as National,Sales Manager for both programs. Reed is ... over 18 years of pharmaceutical sales experience. Most ...
Cached Biology Technology:Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 10Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study ... control leg movements with a National Science Foundation ... four-year project. , Ari Berkowitz, professor in the ... Sciences, will focus on the differences between the ... understand what neurotransmitters they use and what connections ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... brain that controls insulin responses has been shown to ... evidence that the disease can be treated in its ... Rhode Island Hospital and Brown Medical School. , ... prevent several components of neurodegeneration and preserve learning and ...
... known that animals use song as a way of attracting ... unusual way of scaring off predators ?by singing to them. ... that wild gibbons in Thailand have developed a unique song ... survival, the gibbons appear to use the song not just ...
... 21 September, 2006 - Elsevier is delighted to ... the journal Vaccine: HPV Vaccines and Screening in ... provides a comprehensive and invaluable update for paediatricians, ... major donor institutions worldwide. , With the arrival ...
Cached Biology News:Insulin receptor stops progression of Alzheimer's disease 2Insulin receptor stops progression of Alzheimer's disease 3Singing for survival 2Singing for survival 3
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... and 2.0 mL samples for freezing point determinations. Includes built-in printer, keypad, ... with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
Biology Products: